Molecular Beacons for Clinical Cancer Imaging

用于临床癌症成像的分子信标

• 批准号: 6641339
• 负责人: Ella Fung Jones
• 金额: $ 29.85万
• 依托单位: VISEN MEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-15 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6641339
• 关键词: athymic mouse; bioimaging /biomedical imaging; biomarker; biotechnology; cathepsin B; chemical synthesis; colorectal neoplasms; dosage; fluorescent dye /probe; imaging /visualization /scanning; infrared radiation; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; ovary neoplasms; pathologic process; pharmacokinetics

DESCRIPTION (provided by applicant): There is a growing need in the medical imaging sciences to better detect and characterize abnormal tissue and disease processes. Optical imaging in the near-infrared spectrum offers the possibility to employ fluorescently tagged reporter probes to obtain specific molecular information about a particular disease state. VisEn Medical, Inc. is pioneering the development of a novel optical molecular imaging technology platform that enables imaging of molecular activity in-vivo. This proprietary technology platform is based on near-infrared activatible optical probes that become activated only when they come in contact with the specific enzymes that they are designed to target. VisEn is currently developing a Cathepsin B enzyme-imaging probe for early clinical cancer detection. We have chosen to target the enzyme Cathepsin B as it is known to be associated with several different types of cancer, including colon and ovarian cancer, as well as other diseases such as arthritis and cardiovascular disease. The overall goal of this SBIR grant proposal is to test and characterize the different near infrared fluorochrome probes developed during Phase I of this project in different in-vivo disease models in order to select a candidate for clinical trials. The Specific Aims of this Phase II proposal are summarized below. 1. Test at least three different Cathepsin B probes in animal tumor models for their ability to detect cancer. 2. Evaluate the probes for their ability to detect different types of tumors, specifically colorectal and ovarian tumors. 3. Determine key preclinical Cathepsin B probe properties, including the pharmacokinetics, biodistribution and toxicity of the probes. 4. Conduct preliminary formulation and stability studies.

描述（由申请人提供）： 医学成像科学的需求日益增长，以更好地检测和表征异常的组织和疾病过程。近红外光谱中的光学成像提供了使用荧光标记的记者探针获得有关特定疾病状态的特定分子信息的可能性。 Visen Medical，Inc。正在开发一种新型的光学分子成像技术平台的开发，该平台可以在体内进行分子活性的成像。该专有技术平台基于近红外的活化光学探针，仅当它们与靶向靶向的特定酶接触时才被激活。 Visen目前正在为早期临床癌症检测开发组织蛋白酶B酶模仿探针。我们选择靶向酶组织B，因为众所周知，它与包括结肠癌和卵巢癌等多种类型的癌症以及其他疾病（例如关节炎和心血管疾病）有关。该SBIR赠款提案的总体目标是测试和表征该项目在不同的体内疾病模型中I阶段开发的不同近红外荧光色素探针，以便选择临床试验的候选者。该II阶段提案的具体目的如下总结。 1。在动物肿瘤模型中至少测试了至少三种不同的组织蛋白酶B探针，以检测癌症的能力。 2。评估探针是否检测到不同类型的肿瘤，特别是结直肠癌和卵巢肿瘤的能力。 3。确定关键的临床前组织蛋白酶B探针特性，包括探针的药代动力学，生物分布和毒性。 4。进行初步配方和稳定研究。